Psoriatic Arthritis
Recap
Expanding Treatment Options for Psoriatic Arthritis in Adults
Biologic therapies have transformed the treatment of psoriatic arthritis (PsA) in adults. In this ReCAP, Dr Eric Ruderman discusses the efficacy...
Feature
Therapeutic Drug Monitoring in Rheumatology: A Promising Outlook But Many Barriers to Overcome
Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome before it’s widely...
News from the FDA/CDC
FDA Approves Ustekinumab Biosimilar Otulfi
This is the fourth ustekinumab biosimilar approved in the United States.
Feature
Direct-to-Consumer Testing’s Expansion to Rheumatology Has Benefits but Potential Risks
Rheumatologists and lab specialists generally support consumers’ ability to access tests without a doctor’s order, but they remain aware of the...
News from the FDA/CDC
Bimekizumab Gains FDA Approval for Psoriatic Arthritis, Axial Spondyloarthritis
The drug is the first and only dual IL-17A and IL-17F inhibitor approved to treat four chronic immune-mediated inflammatory diseases.
Feature
Rheumatology Clinic Interventions for Smoking, Blood Pressure ‘Make a Big Difference’
Dr. Christie Bartels discussed how rheumatology clinics can be utilized to tackle two common risk factors for heart disease without adding...
Latest News
Topical Tapinarof and Roflumilast for Psoriasis: Where Do they Fit In?
“They’re very fast-acting, effective,” and result in a large improvement over steroids, Dr. Jashin Wu said.
Feature
Ustekinumab’s ‘Egregious’ Medicare Part B and D Pricing Differences Led to Federal Intervention
OIG reports showed a spike in ustekinumab costs for patients in Medicare Part D. Experts said Inflation Reduction Act changes in Medicare drug...
News
New Associations Identified Between IBD and Extraintestinal Manifestations
Overall, 14% of patients had at least one extraintestinal manifestation.
Latest News
TYK2 Inhibitor Effective for Psoriasis in Phase 2 Study
At week 12, PASI 75 was achieved by 18%, 44%, 68%, and 67% of patients receiving zasocitinib at doses of 2 mg, 5 mg, 15 mg, and 30 mg,...
From the Journals
Patients With Immune-Mediated Inflammatory Diseases, Type 2 Diabetes Reap GLP-1 Receptor Agonist Benefits, Too
GLP-1 RAs were associated with a decreased risk for all-cause mortality and major adverse cardiovascular events in patients with immune-mediated...